Buy Rating for Viridian Therapeutics on VRDN-001 Clinical Advancements and Market Potential
Strength Seen in Viridian Therapeutics (VRDN): Can Its 8.7% Jump Turn Into More Strength?
Viridian Therapeutics Up Over 14%, on Pace for Largest Percent Increase Since January 2023 -- Data Talk
Viridian, Pharvaris Said to Be Among Prime M&A Targets for Biogen
Viridian Therapeutics Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
BTIG Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $46
H.C. Wainwright Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $27
Buy Rating for Viridian Therapeutics Amidst Promising Thyroid Eye Disease Drug Trials
LifeSci Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $46
Buy Rating Affirmed for Viridian Therapeutics Amid Promising TED Treatment Advancements
Viridian Therapeutics Releases Updated Investor Presentation
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $42
Optimistic Outlook for Viridian Therapeutics With Multiple Clinical Milestones Ahead
Express News | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Are Analysts Bullish on Viridian Therapeutics, Inc. (VRDN) Right Now?
Ladenburg Thalmann Maintains Viridian Therapeutics(VRDN.US) With Hold Rating
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $30 to $46
Express News | Wolfe Research Initiates Coverage On Viridian Therapeutics With Outperform Rating
Viridian Therapeutics Price Target Maintained With a $30.00/Share by Needham
Viridian Gains After R&D Update; Wolfe Starts at Outperform